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The 2009 influenza pandemic has introduced the new 
re-assorted influenza A(H1N1)pdm09 virus which recir-
culated during the 2010/11 influenza season. Before 
that season, it was possible to acquire protective 
immunity either by pandemic or seasonal influenza 
vaccination against influenza A(H1N1)pdm09 or by nat-
ural infection. To obtain data on vaccination coverage 
and antibody levels in a reference population and to 
calculate whether or not the herd immunity threshold 
(HIT, calculated as 33% given an R0 of 1.5) was reached 
at the beginning of the 2010/11 season we performed 
a seroprevalence study in November 2010 in Hamburg, 
Germany. Antibody titres were assessed applying a 
haemagglutination inhibition test. Vaccination cov-
erage was very low: 14% for pandemic and 11% for 
seasonal 2010/11 vaccinations. Even in those with 
underlying risk factors, vaccination coverage was 
not much higher: 17% for both vaccines. Serological 
analysis revealed antibody titres of ≥1:10 in 135 of 
352 (38%) and of ≥1:40 in 61 of 352 study participants 
(17%). Specific antibodies were measurable in 26% of 
those without history of vaccination or natural infec-
tion, indicating a high proportion of subclinical and 
mild influenza disease. Nevertheless, the HIT was not 
reached, leaving the majority of the population sus-
ceptible to influenza A(H1N1)pdm09 and its potential 
complications.
Introduction
In April 2009, a new re-assorted influenza A virus 
emerged causing the influenza A(H1N1)pdm09 pan-
demic [1]. In Germany, a monovalent AS03-adjuvanted 
vaccine against the pandemic influenza A(H1N1)pdm09 
(Pandemrix) has been available since October 2009 and 
was recommended to persons at risk for severe disease 
but was also offered to anyone who wanted to be vac-
cinated for maximal personal protection. In addition, 
a trivalent seasonal influenza vaccine was available 
as in previous years [2]. The end of the pandemic was 
declared in August 2010, and haemagglutinin and 
neuraminidase antigens H1 and N1 of the pandemic 
strain were integrated into the 2010/11 trivalent sea-
sonal influenza vaccines, which became available in 
Germany in September 2010. Therefore, antibodies to 
influenza A(H1N1)pdm09 detected in November 2010, 
before the start of the influenza season 2010/11 were 
a consequence either of vaccination with the pandemic 
or the 2010/11 seasonal vaccine or of natural infection.
It was discussed before the 2010/11 influenza season, 
whether or not this unique situation would lead to high 
immunity in the population and thus to a particularly 
mild influenza season, as it was generally assumed 
that the influenza A(H1N1)pdm09 virus would remain 
the predominant virus strain in the 2010/11 season. 
The proportion of a population that must be immune 
to reduce the mean number of secondary infections 
per infectious individual to less than one, is called the 
herd immunity threshold (HIT). The HIT indicates that a 
certain level of population immunity reduces the prob-
ability of infection of non-immune individuals. In viral 
diseases, this particular immunity threshold directly 
depends on the transmission potential of the infec-
tious agent. Direct and indirect protection reduce the 
reproduction rate, eventually stopping or preventing an 
epidemic wave [3].
In addition to vaccine effectiveness and duration of pro-
tection, the degree of vaccine uptake in the population 
during a mass vaccination campaign is essential for 
the mitigation of pandemic influenza. In Germany and 
other countries, there was a significant media-driven 
debate on risks and benefits associated with adjuvan-
ted and non-adjuvanted pandemic influenza vaccines 
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[4]. As a result, vaccination coverage remained low in 
Germany, in the general population and in risk groups 
[5].
In a seroprevalence study in the second largest city 
in Germany, we intended (i) to assess the proportion 
of persons with detectable antibodies against influ-
enza A(H1N1)pdm09 and to estimate whether or not 
the HIT was reached, (ii) to compare antibody titres in 
vaccinated and previously infected persons in general 
and in high risk subgroups, and (iii) to obtain infor-
mation on the acceptance of past pandemic vaccina-




We performed a cross-sectional survey in Hamburg 
between 1 and 21 November 2010. Hamburg is the sec-
ond largest city in Germany with 1.8 million inhabit-
ants. The recruitment period was kept short to allow 
as many seasonal influenza vaccinations as possible 
to happen prior to enrolment, while excluding poten-
tial natural infections that might occur at the beginning 
2010/11 influenza season. Volunteers were recruited 
through advertisements in the city’s public transporta-
tion system. Registration for participation in the survey 
was possible via telephone or internet. Besides age 
above 18 years and ability to understand the informed 
consent process there were no particular in- or exclu-
sion criteria. Basic demographic data, information on 
influenza-like illness, vaccination status as well as 
concomitant diseases or risk factors for complicated 
influenza were obtained using a standardised ques-
tionnaire after having obtained written consent. Each 
questionnaire was reviewed for completeness and 
consistency by a trained member of the investigation 
team together with the participant. Questions included 
whether or not the participant had received the regular 
seasonal influenza vaccine after April 2009 and/or the 
pandemic vaccine. A condition ‘past influenza A(H1N1) 
disease’ (referred to as ‘natural infection’ in this manu-
script) was assumed if the participant reported history 
of influenza diagnosed by a medical doctor or treat-
ment with neuraminidase inhibitors prescribed by a 
medical doctor since April 2009. Questions addressing 
the participants’ opinion on the past vaccination cam-
paigns as well as pandemic vaccines as such included 
whether or not the participant had general concerns 
with respect to adjuvants contained in vaccines and 
if yes, whether he/she would still be willing to receive 
adjuvanted vaccines in future pandemics.
Ethical approval was obtained from the local ethics 
committee of the Hamburg chamber of physicians.
Virological analysis
A serum sample was obtained from each participant, 
centrifuged at 2,000 g for 10 minutes, and stored at 
-80 °C until further processing. The samples were ana-
lysed for antibodies against influenza A(H1N1)pdm09 
virus by an in-house haemagglutination inhibition (HI) 
test which gave clear and highly reproducible results 
and allowed to determine titres of 1:10 against influ-
enza A(H1N1)pdm09 virus (sensitivity 1.0 and specifi-
city 0.96). This in-house HI test has been described in 
detail elsewhere [6]. In brief, the HI-test was designed 
to reach a high specificity without losing relevant sen-
sitivity and could show that there was no cross-reac-
tivity between antibodies against seasonal influenza 
A/Brisbane/59/2007(H1N1) and antibodies against 
influenza A(H1N1)pdm09 influenza (unpublished data). 
The external reference serum pool obtained from the 
National Institute for Biological Standards and Control 
(NIBSC), with a defined titre after multi-laboratory test-
ing of 1:160, however, was reproducibly equivalent to 
a titre of 1:80 (i.e. one two-fold dilution lower) in our 
test.
Statistical analysis
Statistical analyses were performed from anonymised 
data by members of the study team who had not been 
involved in the recruitment and questionnaire proce-
dures. For calculating the HIT, we used a basic repro-
duction number (R0) of 1.5 which was assumed to be 
the most realistic by the European Centre for Disease 
Prevention and Control (ECDC) [7]. This R0 lies within a 
range between 1.2 and 1.7, which has been reported for 
Europe and the United States of America [8,9]. Using 
the simplified equation to calculate the HIT=(R0–1)/R0 
[10], protective antibody titres would have been neces-
sary in at least 33% (17–41%) of the population to pre-
vent a significant influenza wave in the 2010/11 season.
Results
Of the 353 study persons, 169 (48%) were male. 
Median age was 39 years (range 18–78), see Figure. 
Co-morbidities including diabetes, cancer, immuno-
suppression, and chronic liver or kidney disease were 
present in 52 of 353 individuals (15%).
Vaccination coverage for pandemic (49/353, 14%) and 
2010/11 seasonal (40/353, 11%) influenza was very 
low. Ten participants (2.8%) reported to have been 
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diagnosed with influenza (n=2) or to have been treated 
with neuraminidase inhibitors (n=8) since April 2009 
and were, hence, classified as probable ‘natural infec-
tions’. Seventy-nine individuals (22%) reported evi-
dence for at least one of the three options, pandemic 
vaccination, seasonal 2010/11 vaccination or natural 
infection, for acquisition of specific antibodies. Of the 
52 persons with co-morbidities, nine stated to have 
received the pandemic vaccine and a further nine 
stated to have received the 2010/11 seasonal influenza 
vaccine. Four had been vaccinated with both vaccines.
Serological analysis of the entire study population 
revealed influenzaA(H1N1)pdm09 antibody titres of 
≥1:10 in 135 of 352 (38%) and of ≥1:40 in 61 of 352 (17%) 
samples (Table 1), which is below the calculated HIT of 
33% for the ≥1:40 levels. A titre of ≥1:20 (which repre-
sents a titre of ≥1:40 in the external NIBSC-reference 
serum pool and is often deemed as protective) was 
reached by 97 of 352 (28%).
Proportions of subjects with antibody titres in the three 
subgroups (i) pandemic vaccination, (ii) seasonal influ-
enza 2010/11 vaccination, and (iii) ‘natural infection’ 
are shown in Table 1 for titres ≥1:10 and ≥1:40. Among 
pandemic vaccine recipients, antibody titres ≥1:10 were 
detected in 39 of 49 and titres ≥1:40 in 23 of 49 people 
one year (range 8–14 months) after vaccination with 
the pandemic vaccine. Similar proportions of antibody 
titres of ≥1:10 and ≥1:40 were detected in those that 
had received the 2010/11 seasonal influenza vaccine 
shortly (0–10 weeks) before participating in this study: 
36 of 40 vaccine recipients had antibody titres ≥1:10, 
22 of 40 had titres ≥1:40. Among the 14 individuals who 
were sequentially immunised with both the pandemic 
and seasonal influenza 2010/11 vaccines, 13 exhibited 
titres ≥1:10 and nine titres ≥1:40. Interestingly, anti-
body titres ≥1:10 were detected in 71 of 272 (26%) of 
individuals without any history of either disease or 
vaccination (24/272 (9%) for titres ≥1:40), indicating 
asymptomatic infection in about a quarter of all par-
ticipants (Table 1). Yet the proportion of individuals 
with positive antibody titres was significantly higher 
in those with a history of vaccination and/or disease 
than in those without for both titres, ≥1:10 (80% versus 
26%, P<0.0001) and ≥1:40 (47% versus 9%, P<0.0001).
Overall, the proportion of vaccinated individuals with 
high antibody levels (≥1:40) decreased with age in 
all subgroups while such a trend was not obvious for 
those with antibody levels ≥1:10 (Table 1). Proportions 
of subjects with titres ≥1:10 and ≥1:40 were comparable 
in those with and without co-morbidities (≥1:10 titres: 
46% versus 37%, P=0.2; ≥1:40 titres: 15% versus 18%, 
P=0.7).
When asked about their personal opinion about past 
pandemic vaccination strategies, 58% of the partici-
pants stated that mass vaccinations and respective 
campaigns in 2009 were not justified in retrospect. 
However, 63% would accept to receive pandemic vac-
cinations in future pandemic situations. Twenty-two 
percent (76/353) stated to have concerns regarding the 
adjuvant that was included in the pandemic vaccine. 
Yet 61% (46/76) of them would be open for future pan-
demic vaccinations despite their adjuvant-related con-
cerns (Table 2).
Table 1
Antibody titres against influenza A(H1N1)pdm09 in the study population, stratified by age group and antibody level, after 
vaccination or natural infection, Hamburg, Germany, 1–21 November 2010 (n=353)
Study participants 18–39 years 40–59 years ≥60 years All




































No evidence for natural infectiona or vaccination Number (%) 154/193 (80) 99/125 (79) 20/35 (57) 273/353 (77)
HI-test results
Titre ≥1:10 (%)






















a ‘Natural infection’ was defined as influenza disease diagnosed by a physician or treatment with neuraminidase inhibitors since April 2009.
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Discussion
In the present study, the calculated HIT was not met 
for protective antibody levels as neither a protective 
titre of ≥1:40 nor a titre of ≥1:20 was reached by 33% 
of the study population. Approximately one third of 
all participants showed measurable antibody titres of 
≥1:10 but this titre lies below the protective level (see 
below). This reflects a rather low proportion with pro-
tective or even detectable antibody levels in the study 
population about one and a half years after the pan-
demic and roughly one year after pandemic mass vac-
cinations in Hamburg, Germany. The true proportion of 
people with measurable antibody titres in the general 
population is likely to be even lower than the numbers 
presented here due to potential recruitment bias in 
our study population: the participants may have had a 
more positive view on influenza vaccinations than the 
general population.
When this study was conducted in November 2010 just 
before the beginning of the 2010/11 influenza season, 
antibodies against influenza A(H1N1)pdm09 could be 
detected in the majority of those who had received 
pandemic vaccination in late 2009 as well as also in 
those who had received seasonal 2010/11 influenza 
vaccination recently. While during the pandemic almost 
exclusively the adjuvanted influenza vaccine had been 
used in Germany, almost all trivalent influenza vac-
cines used in the 2010/11 season were non-adjuvanted 
vaccines. Assuming that immunity lasts longer after 
administration of adjuvanted vaccines (unpublished 
results), this might explain why the prevalence of ≥1:10 
and ≥1:40 antibody titres was similar between the two 
groups of vaccine recipients even though the pandemic 
vaccine was administered one year earlier. However, 
in some study participants the determination of anti-
bodies may have been performed too soon after vac-
cination to detect high antibody titres induced by the 
2010/11 seasonal vaccine. Interestingly, a high pro-
portion of individuals without history of vaccination 
or infection had detectable antibody levels. This indi-
cates a high rate of infections with a subclinical or mild 
clinical course in the study population, which is in line 
with other seroprevalence studies [11-14]. In a recently 
published report by von Kries et al., who compared 
influenza A(H1N1)pdm09-specific antibody titres in 
unvaccinated children in Germany before and after the 
pandemic, the serologically determined incidence of 
pandemic influenza was as high as 25.4% in the age 
group of 1–4 year-olds and 28% in children aged 5–17 
[6].
Overall, the proportion of vaccinated individuals with 
high antibody levels (≥1:40) decreased with age in 
all subgroups possibly reflecting declining immune 
response with age. However, this potentially waning 
immune response in the elderly was not seen at the 
≥1:10 antibody level in the vaccinated subgroups pos-
sibly indicating that vaccination confers better immune 
response than asymptomatic infection. Vaccination 
coverage was also low in participants with co-morbid-
ities generally accepted to confer a high risk for com-
plicated influenza disease [1], and antibody levels in 
this group were not significantly higher compared to 
antibody levels in individuals without risk factors. This 
implies that immune protection of the sub-population 
with risk factors may have been insufficient before the 
past 2010/11 influenza season.
It is not fully established how well HI antibody titres 
reported in the literature correlate with protection from 
disease, but generally a HI-titre of ≥1:40 is regarded to 
indicate protection [15]. The in-house HI test used in 
this study was designed to be highly specific, which 
resulted in a two-fold lower titre when testing the exter-
nal reference serum pool obtained from the NIBSC. 
Consequently, titres of 1:20 are equivalent to 1:40 titres 
obtained by less stringent HI-tests [6]. On the other 
hand, recently published preliminary data from the 
Influenza Monitoring Vaccine Effectiveness in Europe 
(I-MOVE) network indicate low vaccine effectiveness 
of the seasonal 2010/11 influenza vaccine [16,17]. Data 
from the United Kingdom, for example, have shown a 
vaccine effectiveness of the pandemic and the 2010/11 
seasonal influenza vaccines against RT-PCR-confirmed 
influenza in the 2009/10 and 2010/11 seasons of 34% 
and 46%, respectively, and of 63% in those who were 
vaccinated in both seasons [18]. In an accompanying 
editorial, Puig-Barbera hypothesised the test-negative 
study design of the observational study or adjustments 
Table 2
Vaccination history of the study participants, their concerns related to the adjuvanted pandemic vaccine and their 
willingness to receive pandemic vaccination in the future, Hamburg, Germany, 1–21 November 2010 (n=353)
Question Answer All Male (n=169) Female (n=184)
Have you received 2009/10 seasonal influenza vaccination? Yes 82 (23%) 45 (27%) 37 (20%)
Are you planning 2010/11 seasonal influenza vaccination? Yes 75 (21%) 37 (22%) 38 (21%)
Have you ever been vaccinated against seasonal influenza? Yes 182 (52%) 91 (54%) 91 (49%)
Do you have concerns regarding adjuvants used in the pandemic vaccine? Yes 76 (22%) 31 (18%) 45 (24%)
Would you agree to receive pandemic vaccination in the future?
Yes 




46/76 (61%) 20/31 (65%) 26/44 (59%)
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for some variables in the analyses might have led to 
an underestimation of the vaccine effectiveness [19]. 
When applying an arbitrary cut-off titre of ≥1:40, our 
data are in line with the observed low vaccine effec-
tiveness. Nevertheless, influenza A(H1N1)pdm09 anti-
bodies were significantly more often detected in those 
who had received pandemic or seasonal vaccination 
than in those that had not. Interestingly, in our study 
the small number of participants who had been vacci-
nated with both the pandemic and the seasonal vac-
cine exhibited highest antibody titres of ≥1:10 in 93% 
and ≥1:40 in 64%, possibly suggesting a prime-boost 
effect.
Vaccination coverage was very low in our study popu-
lation. In Sweden, vaccination coverage with the same 
pandemic vaccine was higher than 60% in the general 
population and higher than 95% in healthcare workers 
[20]. According to a representative telephone survey, 
vaccination coverage in Hamburg after the influenza 
A(H1N1)pdm09 vaccination campaign was as low as 
8.4% (95% confidence interval: 4.9–14.0) [12]. The fact 
that the vaccination coverage in our study population 
was higher than in the telephone survey suggests our 
study sample may have suffered from a recruitment 
bias as discussed above. Nevertheless, as other stud-
ies also found low vaccination coverage for pandemic 
influenza in Hamburg and other German regions [4], 
it is reasonable to assume that our data on vaccine-
induced immunity can be generalised for the entire 
German population.
In Germany, there was a vivid media-driven debate on 
risks and benefits associated with the mass vaccina-
tion campaigns and the adjuvant containing squalene 
used in pandemic vaccines [4,5]. A high proportion of 
participants stated to have had reservations regarding 
the adjuvant and the usefulness of the mass vaccina-
tion campaigns. Nevertheless, concerns related to the 
adjuvant did not influence the participants’ willingness 
to receive pandemic vaccination in the future. This 
could be interpreted to indicate that the low vaccina-
tion coverage in our study population (and possibly 
in all of Germany) was related to personal distrust of 
mass vaccination campaigns and adjuvants in general 
rather than of the effectiveness of the pandemic vac-
cine. This information could be important for planning 
health protection measures in future pandemics in that 
it may be important to provide more detailed informa-
tion on the vaccine and to justify both active and non-
active ingredients, i.e. the form of the active ingredient 
(whole virion versus split/subunit vaccines), the adju-
vant as well as non-active excipients.
The present study has several limitations. In addition 
to the recruitment bias, the way this study was con-
ducted includes the risk of recall bias in that some par-
ticipants may not exactly remember the type and date 
of vaccinations received one and a half years before the 
study or may be unable to provide reliable information 
on influenza-like illness. We do not think, however, that 
this had a significant impact on our major findings as 
the study participants are likely to remember precisely 
whether or not they have received pandemic vaccina-
tion because of the particular circumstances around the 
pandemic vaccinations (such as information, specific 
locations or waiting lists), while seasonal 2010/11 vac-
cination has only been available for a few weeks prior 
to this study. Furthermore, information bias may have 
been introduced by imprecise definitions; for example, 
the definition of ‘natural infection’ may not reflect true 
influenza infection due to the unspecific disease symp-
toms and the fact that influenza disease is usually not 
confirmed by laboratory testing. We are also aware of 
the fact that the exclusion of children and adolescents 
limit our findings because these groups are at high 
risk for influenza A(H1N1)pdm09 infection and impor-
tant for its transmission [6]. While the sex distribution 
in the study population resembled the general popula-
tion in Hamburg and Germany overall, the age distribu-
tion differed in that a comparatively high number was 
recruited in the younger age groups while the elderly 
population was underrepresented [21]. Nevertheless, 
the population recruited for this survey through adver-
tisements in the public transport system represented a 
relevant population with respect to influenza transmis-
sion that was representative for the city of Hamburg as 
well as other regions in Germany. Finally, a few persons 
with positive antibody titres may have been missed by 
using the in-house HI test alone without adding the 
sensitivity of a second test (i.e. a microneutralisation 
test), but we think that a slight increase in sensitivity 
would have had a negligible influence on the results 
[15].
In conclusion, the HIT for influenza A(H1N1)pdm09 had 
not been reached in Hamburg, Germany by November 
2010, leaving the majority of the population suscep-
tible to the infection and its potential complications, 
although everyone had the chance to acquire specific 
immunity either during the mass vaccination cam-
paign in 2009 (which targeted the total population in 
Germany), during routine seasonal influenza vaccina-
tion in 2010 (targeting specific risk groups) or by natu-
ral infection. Our data confirm the view that vaccination 
and potentially re-vaccination with influenza A(H1N1)
pdm09-containing vaccines in 2009/10 and 2010/11 
induced measurable specific antibodies. It is impor-
tant to increase the proportion of immune persons in a 
population above the HIT with effective and fast acting 
vaccines especially in a pandemic situation character-
ised by a general lack of pre-existing specific immu-
nity. While protective antibody titres against influenza 
viruses have been well defined for the purpose of 
assessing immunogenicity of vaccines, their correla-
tion with clinical protection especially with regard to 
long-term protection is less clear. Therefore it seems 
important to validate the currently used serological 
correlates of protection against influenza viruses [15] 
and to continue the monitoring of breakthrough infec-
tions in observational studies during future influenza 
seasons as it has been done by I-MOVE.
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